Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics shares are rising following the CDC's announcement that free at-home COVID-19 test delivery programs will resume in late September.
August 23, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Co-Diagnostics shares are trading higher due to the CDC's announcement of the reopening of free at-home COVID-19 test delivery programs.
The CDC's decision to reopen free at-home COVID-19 test delivery programs directly benefits Co-Diagnostics, a company involved in COVID-19 testing. This news likely increases demand for their products, positively impacting their stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90